Jacob J. Adashek DO

PubMed

• 2 citations
  Ag(e)nostic precision oncology therapy approvals across the years.
  Matthew R Kudek, Jacob J Adashek, Razelle Kurzrock
  Trends in Cancer. 2025-08-01
• 1 citations
  Gene- and immune-targeted therapy combinations using dual-matched biomarkers for patient selection.
  Daisuke Nishizaki, Razelle Kurzrock, Jacob J Adashek, Ki Hwan Kim, Hyo Jeong Lim
  NPJ Precision Oncology. 2025-07-24
• 6 citations
  Tumour-agnostic kinase inhibitors.
  Jacob J Adashek, Mina Nikanjam, Razelle Kurzrock
  Nature Reviews. Drug Discovery. 2025-07-01

Journal Articles

• Infectious Complications of Mucositis in Postchemotherapy Neutropenic Cancer Patients: Three Case Reports and a Review of the Literature  
  Shah N, Adashek JJ, Molinas NL, Ramsakal A, Greene JN, Infectious Diseases in Clinical Practice, 9/2019
• The role of metastasectomy in the treatment of metastatic renal cell carcinoma  
  Adashek JJ, Aydin AM, Kim P, Spiess PE, AME Medical Journal, 6/28/2019

Abstracts/Posters

• LAG3 transcriptomic expression correlates with high levels of PD-1, PD-L1, PD-L2, and CTLA-4 checkpoints and with high tumor mutational burden across cancers.
  Adashek JJ, Kato S, Pabla S, Nesline M, Conroy JM, Subbiah V, DePietro P, Kurzrock R., 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, Illinois, 6/5/2022
• Immunoregulatory Molecule Expression Patterns Before and After Immune Checkpoint Inhibition: A Pilot Study
  Adashek JJ, Welence T, Lee S, Mareboina M, Koga M, Koga T, Pabla S, Glenn S, Nesline M, Conroy J, DePietro P, Kato S, Kurzrock R, 2021 JCA-AACR Precision Cancer Medicine International Conference Virtual, 9/22/2021
• The landscape of 2,706 RET alterations from 89,754 adult patients with cancer: Clinical implications
  Adashek JJ, Andreev-Drakhlin A, Roszik J, Desai AP, Subbiah V, 2021 American Association for Cancer Research (AACR), Virtual, 4/10/2021